http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2009101321-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A21D13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-0106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2417 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2411 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2414 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A21D8-042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23K20-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A21D2-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A21D8-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L7-104 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-26 |
| filingDate | 2007-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2009101321-A |
| titleOfInvention | POLYPEPTIDE |
| abstract | 1. The PS4 variant polypeptide derived from the parent polypeptide having amylase activity, wherein said PS4 variant polypeptide contains an amino acid substitution at position 307 for lysine (K) or arginine (R), according to the numbering of the positions of the Pseudomonas saccharophilia exoamylase sequence provided in SEQ ID NO: 1.! 2. The PS4 variant polypeptide of claim 1, derived from a parent polypeptide having exoamylase activity, preferably non-maltogenic exoamylase activity. ! 3. The PS4 variant polypeptide of claim 1, wherein the amino acid substitution at position 307 is a lysine substitution (307K), preferably H307K, or an arginine substitution (307R), preferably H307R. ! 4. The polypeptide of the PS4 variant according to claims 1, 2 or 3, which further includes an amino acid substitution at position 70.! 5. The PS4 variant polypeptide of claims 1, 2, or 3, wherein the amino acid substitution at position 70 is an aspartic acid (70D) substitution, preferably G70D. ! 6. The PS4 variant polypeptide according to claims 1, 2 or 3, wherein the amino acid at position 272 of the PS4 variant polypeptide sequence is histidine (H). ! 7. The PS4 variant polypeptide according to claims 1, 2, or 3, wherein the amino acid at position 303 of the PS4 variant polypeptide sequence is glycine (G). ! 8. The polypeptide of the PS4 variant according to claims 1, 2 or 3, where the polypeptide of the PS4 variant further comprises one or more mutations selected from the group consisting of: 33, 34, 121, 134, 141, 146, 157, 161, 178 , 179, 223, 229, 309 or 334.! 9. The PS4 variant polypeptide according to claims 1, 2 or 3, wherein the additional mutation (s) of the PS4 variant polypeptide is selected (s) from the group consisting of: 33Y, 34N, 121F, 134R, 141P, 146G, 157L, 161A, 178F, 179T, 223E, 229P, 309P, 334P, preferably N33Y, D34N, G121F, G134R, A141P, Y14 |
| priorityDate | 2006-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.